https://acpinternist.org/archives/2020/01/recalls-research-for-generic-drug-safety.htm. Image by AntonioGuillem. Probable carcinogens have been found in angiotensin-receptor blockers, but experts say generic drugs remain ... Choudhry. “Recent events
News coverage of drug-contaminated water samples in Philadelphia and 24 other U.S. ... Daughton and Ilene Sue Ruhoy. Drug Safety 2008; 31(12): 1069-1082. White House Office of National Drug Control Policy position statement.
FDA Drug Safety Communication. FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. ... Accessed on Sept. 14, 2016. FDA Drug Safety Communication. FDA revises warning regarding use of
A drug safety communication about over-the-counter acne products (including Proactiv, Neutrogena, MaxClarity, Oxy, Ambi, Aveeno, Clean & Clear) and the risk of rare but potentially life-threatening allergic reactions or ... The agency will, however,
But SGLT2 inhibitors have recently been linked to 20 cases of diabetic ketoacidosis (DKA), as noted in a May 15 drug safety communication from the FDA. ... start. A patient who knows you will update them as information accumulates is a partner in
with the drug are likely to outweigh its potential risks for each patient. ... Approved on the fast track as an orphan drug, safety and efficacy were evaluated in 4 clinical trials including 547 treated patients.
A labeling update and drug safety communication on low-molecular-weight heparin, including enoxaparin, regarding the risk of spinal column bleeding and subsequent paralysis after spinal injections, including epidural procedures and ... Safety and
dose should exceed 16 mg, according to the agency's drug safety communication online. ... The FDA is continuing to evaluate multiple sources of data in the ongoing safety review of this issue but has not changed its recommendations regarding the drug.
Rutgers University in Newark, N.J., and president of BLCMD Associates LLC in Chapel Hill, N.C., which offers consulting services in drug safety. ... Indeed, in the November 2011 Drug Safety, researchers published a study examining the prescription data
It's also recommended that clinicians discontinue the drug in patients with symptoms of liver injury. ... A drug safety communication about the risk of name confusion between ado-trastuzumab emtansine (Kadcyla) and trastuzumab (Herceptin).